Biotechs continued to reshape pipelines as late‑stage and early‑stage programs were terminated or reprioritized. Verastem Oncology halted a Phase 1/2 lung cancer study of its MEK inhibitor Avmapki and signaled a strategic pivot toward a KRAS‑targeting program. The company cited a judgment that a different mechanism could deliver greater patient benefit. Separately, Genmab terminated development of acasunlimab, a bispecific antibody it had formerly co‑developed with BioNTech. The decision follows BioNTech’s exit from the asset and reflects portfolio rationalization in the face of shifting clinical priorities and competitive landscapes. Program terminations underscore ongoing repricing of clinical risk and will force companies to reallocate resources toward higher‑confidence assets or seek new partnerships.